LL-37 protects rats against lethal sepsis caused by gram-negative bacteria.

Antimicrobial Agents and Chemotherapy
Oscar CirioniGiorgio Scalise

Abstract

We investigated the efficacy of LL-37, the C-terminal part of the only cathelicidin in humans identified to date (termed human cationic antimicrobial protein), in three experimental rat models of gram-negative sepsis. Adult male Wistar rats (i) were given an intraperitoneal injection of 1 mg Escherichia coli 0111:B4 LPS, (ii) were given 2 x 10(10) CFU of Escherichia coli ATCC 25922, or (iii) had intra-abdominal sepsis induced via cecal ligation and puncture. For each model, all animals were randomized to receive intravenously isotonic sodium chloride solution, 1-mg/kg LL-37, 1-mg/kg polymyxin B, 20-mg/kg imipenem, or 60-mg/kg piperacillin. Lethality; growth of bacteria in blood, peritoneum, spleen, liver, and mesenteric lymph nodes; and endotoxin and tumor necrosis factor alpha (TNF-alpha) concentrations in plasma were evaluated. All compounds reduced lethality compared to levels in controls. Endotoxin and TNF-alpha plasma levels were significantly higher in conventional antibiotic-treated rats than in LL-37- and polymyxin B-treated animals. All drugs tested significantly reduced bacterial growth compared to saline treatment. No statistically significant differences between LL-37 and polymyxin B were noted for antimicrobial and...Continue Reading

References

Sep 21, 1991·Lancet·M P GlauserJ Cohen
Sep 15, 1991·Annals of Internal Medicine·R C Bone
Mar 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R P WenzelL Young
Dec 1, 1996·Infection and Immunity·M GoughN M Kelly
Jan 1, 1997·Advances in Immunology·C E HackL G Thijs
Mar 28, 1998·Antimicrobial Agents and Chemotherapy·J J DrabickA S Cross
Jan 23, 1999·The New England Journal of Medicine·A P Wheeler, G R Bernard
Feb 27, 1999·Current Opinion in Immunology·R J Ulevitch, P S Tobias
Sep 2, 1999·Critical Care Medicine·J D EdgeworthS J Eykyn
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·R E Hancock, M G Scott
Jan 3, 2001·The British Journal of Surgery·S J Parker, P E Watkins
Aug 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·V SupajaturaH Ogawa
Jan 5, 2002·Expert Opinion on Investigational Drugs·R L Añel, A Kumar
Mar 2, 2002·The Lancet Infectious Diseases·R E Hancock
Nov 29, 2002·Current Drug Targets. Infectious Disorders·J A Yethon, C Whitfield
Nov 30, 2002·Expert Opinion on Investigational Drugs·Sanjay ManochaAnand Kumar
Jan 31, 2003·Expert Opinion on Investigational Drugs·Vinay K Sharma, R Phillip Dellinger
Feb 1, 2003·BMJ : British Medical Journal·Pierre-Yves Bochud, Thierry Calandra
Aug 22, 2003·Journal of Internal Medicine·H G Boman
Sep 10, 2003·Journal of Leukocyte Biology·Margherita Zanetti
Oct 18, 2003·American Journal of Respiratory and Critical Care Medicine·Andrea GiacomettiGiorgio Scalise
Feb 18, 2004·The Journal of Clinical Investigation·Jon Mallen-St ClairPaul J Wolters
Mar 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Dawn M E BowdishRobert E W Hancock
May 18, 2004·The Journal of Clinical Investigation·Guangxun MengCarsten J Kirschning
Dec 16, 2004·Critical Care Medicine·Andrea GiacomettiGiorgio Scalise
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Dawn M E BowdishRobert E W Hancock

❮ Previous
Next ❯

Citations

Jan 6, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Robert BuckiWojciech Sokołowski
Feb 12, 1998·Trends in Pharmacological Sciences·B Robertson
Feb 5, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Christina L Thomas-VirnigB Lynn Allen-Hoffmann
Jun 15, 2007·Journal of Perinatology : Official Journal of the California Perinatal Association·R D ChristensenG L Snow
Sep 4, 2008·The Journal of Biological Chemistry·Linda TomasinsigMargherita Zanetti
Jun 19, 2010·The Journal of Antimicrobial Chemotherapy·Maria PräntingDan I Andersson
Sep 10, 2008·Antimicrobial Agents and Chemotherapy·Oscar CirioniAndrea Giacometti
Apr 12, 2012·Antimicrobial Agents and Chemotherapy·Sheng-An LiYun Zhang
Jun 29, 2012·Journal of Innate Immunity·Ka-Yee ChoiNeeloffer Mookherjee
Jan 11, 2013·Critical Care : the Official Journal of the Critical Care Forum·Tobias SchuerholzGernot Marx
Oct 27, 2011·PloS One·Aaron ScottClifford C Taggart
Apr 4, 2008·Molecular Medicine·Lars SteinstraesserTobias Hirsch
Nov 19, 2008·Molecular Medicine·Roland PálffyPeter Celec
Oct 30, 2009·International Journal of Molecular Sciences·Lars SteinstraesserSammy Al-Benna
Nov 16, 2013·Nature Chemical Biology·Ashley L HilchieRobert E W Hancock
Aug 2, 2007·Expert Opinion on Therapeutic Targets·Neeloffer MookherjeeRobert E W Hancock
Aug 31, 2007·Expert Opinion on Biological Therapy·Christian HerrRobert Bals
Oct 27, 2015·Molecular Medicine Reports·Mohamed Mohamed SolimanOsama Moseilhy Saleh
Apr 10, 2012·The Journal of Surgical Research·Oliver StahlSoeren Torge Mees
Jan 19, 2016·Allergologia et immunopathologia·F DilekE Cakir
Jul 7, 2009·International Journal of Antimicrobial Agents·Sakawrat KanthawongSuwimol Taweechaisupapong
Oct 14, 2008·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhuying GuoZhimei Xu
May 28, 2009·Journal of Peptide Science : an Official Publication of the European Peptide Society·Linda TomasinsigAlessandro Tossi
Oct 20, 2010·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Katarzyna LeszczyńskaRobert Bucki
Jul 1, 2014·British Journal of Pharmacology·Prashant ShuklaPrabhat Ranjan Mishra
Nov 12, 2015·Biochimica Et Biophysica Acta·Daniela XhindoliAlessandro Tossi
Nov 14, 2014·Chemical Biology & Drug Design·Erin E GillRobert E W Hancock
Sep 3, 2014·The Biochemical Journal·Ariane NeumannMaren von Köckritz-Blickwede

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.